{"id":33639,"date":"2023-08-23T10:07:25","date_gmt":"2023-08-23T08:07:25","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=33639"},"modified":"2023-10-19T15:05:00","modified_gmt":"2023-10-19T13:05:00","slug":"neue-therapieoptionen-bei-alzheimer-demenz-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2023\/neue-therapieoptionen-bei-alzheimer-demenz-cme","title":{"rendered":"Neue Therapieoptionen bei Alzheimer-Demenz? [CME]"},"content":{"rendered":"<p>In Deutschland sind von 83\u00a0Mio. Einwohnern etwa 700.000\u00a0Menschen an einer Alzheimer-Demenz (AD) erkrankt, und jedes Jahr wird die Diagnose bei 200.000\u00a0Menschen neu gestellt (Pr\u00e4valenz um 1%;\u00a0). Die Sch\u00e4tzungen f\u00fcr \u00d6sterreich f\u00fcr das Jahr 2030 lauten: Pr\u00e4valenz 117.000 und Inzidenz 24.000, bei 9\u00a0Mio. Einwohnern . Etwa 15% der Betroffenen sind zwischen 65 und 74\u00a0Jahre, 50% zwischen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In Deutschland sind von 83\u00a0Mio. Einwohnern etwa 700.000\u00a0Menschen an einer Alzheimer-Demenz (AD) erkrankt, und jedes Jahr wird die Diagnose bei 200.000\u00a0Menschen neu gestellt (Pr\u00e4valenz um 1%;\u00a0). Die Sch\u00e4tzungen f\u00fcr \u00d6sterreich f\u00fcr das Jahr 2030 lauten: Pr\u00e4valenz 117.000 und Inzidenz 24.000, bei 9\u00a0Mio. Einwohnern . Etwa 15% der Betroffenen sind zwischen 65 und 74\u00a0Jahre, 50% zwischen [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5895,2863,5888,5890,5887,5894,5892,5891,745,5896,5889,5893],"class_list":["post-33639","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-a4-studie","tag-aducanumab","tag-amyloid","tag-amyloid-targeting-therapie","tag-beta-amyloid","tag-clarity-ad-studie","tag-donanemab","tag-lecanemab","tag-m-alzheimer","tag-solanezumab","tag-tau-proteine","tag-trailblazer-alz-2-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/33639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=33639"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/33639\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=33639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=33639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=33639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}